Medical devices, healthcare technology and the business of care
PMA approval · P250021

saypha ChiQ

Croma-Pharma GmbH · Decision date Jun 12, 2026

MEDTECHLEDGER EXPLANATIONP250021

What did the FDA approve?

The FDA listed an approval decision dated 2026-06-12 for saypha® ChiQ™, submitted by Croma-Pharma GmbH under PMA number P250021. The product is categorized as an implant, dermal, for aesthetic use, with product code LMH, and is filed under the General and Plastic Surgery specialty. The source statement describes the device as indicated for cheek augmentation and restoring midface volume deficits in patients over the age of 21, administered by subcutaneous and/or supraperiosteal injection.

The record does not specify a supplement type or supplement reason, so the particular change addressed by this action is not identified in the supplied fields; the scope described is the indication and administration route quoted above. This is the labeled purpose reported in the source, not independent proof of safety or clinical effectiveness. The identifier alone does not establish a relationship to an earlier PMA, so none is asserted here; the entry is not a new approval of a whole system.

FDA approval order statement

saypha ChIQ is indicated for use in cheek augmentation and restoring midface volume deficits in patients over the age of 21. The device is indicated to be administered by subcutaneous and/or supraperiosteal injection.
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Jun 12, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250021
Regulatory pathway
Premarket approval application
Product code
LMH
Decision code
APPR
Decision date
Jun 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250021 received

    Application receipt date recorded by FDA.

  2. P250021 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250021

Product / regulatory recordCompanyPathwayDecision dateSource
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
Restylane ContourP140029/S058
Q-Med ABPMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Croma-Pharma GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Industriezeile 6, Leobendorf, 2100

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records